Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $3.86 Consensus Target Price from Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has received an average rating of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $3.8571.

Several research firms recently commented on RVPH. Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, October 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $2.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday, October 28th. Citigroup reiterated a “buy” rating on shares of Reviva Pharmaceuticals in a research note on Friday, August 15th. Finally, HC Wainwright dropped their price objective on Reviva Pharmaceuticals from $11.00 to $4.00 and set a “buy” rating on the stock in a report on Monday, October 27th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Armistice Capital LLC purchased a new position in shares of Reviva Pharmaceuticals in the second quarter valued at about $1,026,000. 683 Capital Management LLC bought a new stake in Reviva Pharmaceuticals during the 2nd quarter valued at approximately $381,000. Persistent Asset Partners Ltd raised its stake in Reviva Pharmaceuticals by 300.0% during the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares during the period. Private Advisor Group LLC purchased a new position in Reviva Pharmaceuticals in the 1st quarter worth approximately $191,000. Finally, XTX Topco Ltd bought a new position in Reviva Pharmaceuticals in the 2nd quarter worth approximately $31,000. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Price Performance

RVPH opened at $0.54 on Friday. Reviva Pharmaceuticals has a fifty-two week low of $0.25 and a fifty-two week high of $4.28. The firm has a market capitalization of $37.52 million, a P/E ratio of -0.83 and a beta of -0.03. The company’s 50-day moving average is $0.51 and its 200 day moving average is $0.59.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. On average, equities research analysts expect that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.